The FDA’s vaccine advisory committee voted in favor of Novavax’s (NVAX) COVID-19 vaccine for use in adults, paving the way for the company to get its first product authorized in the U.S.
But the day-long meeting raised a number of concerns presented by Novavax’s late entry to the vaccine field.
Before any data was even presented, questions were raised by committee members about the need to authorize yet another COVID-19 vaccine, as demand has waned in the U.S., and about the manufacturing…
Source link
